Insider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) CEO Sells 11,964 Shares of Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) CEO Bobak Azamian sold 11,964 shares of the stock in a transaction on Thursday, March 19th. The stock was sold at an average price of $67.00, for a total transaction of $801,588.00. Following the sale, the chief executive officer directly owned 33,421 shares of the company’s stock, valued at $2,239,207. This represents a 26.36% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Tarsus Pharmaceuticals Stock Down 2.2%

Shares of NASDAQ:TARS traded down $1.49 during midday trading on Thursday, reaching $66.75. 461,600 shares of the company were exchanged, compared to its average volume of 672,393. Tarsus Pharmaceuticals, Inc. has a fifty-two week low of $38.51 and a fifty-two week high of $85.25. The stock has a fifty day simple moving average of $69.59 and a two-hundred day simple moving average of $70.20. The company has a current ratio of 3.85, a quick ratio of 3.82 and a debt-to-equity ratio of 0.21.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its earnings results on Monday, February 23rd. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). Tarsus Pharmaceuticals had a negative return on equity of 19.63% and a negative net margin of 14.72%.The firm had revenue of $151.67 million for the quarter, compared to the consensus estimate of $144.56 million. On average, sell-side analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Wall Street Analysts Forecast Growth

TARS has been the topic of a number of recent research reports. Wall Street Zen lowered Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Oppenheimer raised their price target on shares of Tarsus Pharmaceuticals from $95.00 to $105.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Lifesci Capital upgraded shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Monday. The Goldman Sachs Group reissued a “neutral” rating and issued a $68.00 price objective on shares of Tarsus Pharmaceuticals in a research report on Thursday, February 5th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Thursday, January 22nd. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $91.83.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Comerica Bank grew its stake in Tarsus Pharmaceuticals by 470.0% in the fourth quarter. Comerica Bank now owns 855 shares of the company’s stock valued at $70,000 after purchasing an additional 705 shares in the last quarter. Truvestments Capital LLC boosted its holdings in shares of Tarsus Pharmaceuticals by 106.1% in the 4th quarter. Truvestments Capital LLC now owns 909 shares of the company’s stock valued at $74,000 after buying an additional 468 shares during the last quarter. Rockefeller Capital Management L.P. grew its stake in shares of Tarsus Pharmaceuticals by 15.5% in the fourth quarter. Rockefeller Capital Management L.P. now owns 1,283 shares of the company’s stock valued at $105,000 after buying an additional 172 shares in the last quarter. Osaic Holdings Inc. grew its stake in shares of Tarsus Pharmaceuticals by 779.1% in the second quarter. Osaic Holdings Inc. now owns 2,778 shares of the company’s stock valued at $113,000 after buying an additional 2,462 shares in the last quarter. Finally, Leonteq Securities AG acquired a new position in Tarsus Pharmaceuticals during the fourth quarter worth $164,000. 90.01% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Tarsus Pharmaceuticals

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Lifesci Capital upgraded TARS to “Strong‑Buy” and published a set of 2026 estimates that materially narrow expected losses (FY2026 now seen at -$1.01 vs. broader consensus -$3.17) and forecast a positive Q4‑2026 EPS of $0.09 — a clear bullish catalyst that can support upside expectations. Lifesci upgrade report
• Positive Sentiment: Large institutional investors have been increasing stakes (RTW, Deep Track, Jennison, Vanguard, Morgan Stanley among others), keeping roughly 90% institutional ownership — steady buying from big funds tends to support share-price stability and upside over time. MarketBeat TARS coverage
• Neutral Sentiment: Analyst consensus remains mixed‑to‑favorable: the average recommendation is “Moderate Buy” and some firms (Guggenheim, Oppenheimer) have raised targets while others are more cautious — this keeps the outlook constructive but not unanimous. Analyst consensus article
• Neutral Sentiment: Recent quarterly results: revenue beat estimates ($151.7M vs. $144.6M) but EPS slightly missed ($0.20 loss vs. $0.19 expected). Revenue strength is supportive; continued negative margins and guidance keep risk elevated until pipeline milestones materialize. Earnings summary
• Negative Sentiment: Insider selling: Director William J. Link sold 12,500 shares at an average $68.79 on March 16 (disclosed via SEC filing), reducing his stake by ~9.7%. Insider sales can create short‑term downward pressure or be interpreted by some investors as profit‑taking. InsiderTrades report (SEC Form 4)

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.